Uncategorized
Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics for their psychedelic treatments. A third recipient in this batch is Transcend Therapeutics, which is being acquired by Otsuka, according to reports.